Benjamin F. Edwards & Company’s VanEck Pharmaceutical ETF PPH Stock Holding History

Benjamin F. Edwards & Company’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-21	Closed	-$1K	–	1964
2019 Q1	$1K	Hold	21	–	–	﹤0.01%	1658
2018 Q4	$1K	Hold	21	–	–	﹤0.01%	1653
2018 Q3	$1K	Hold	21	–	–	﹤0.01%	1554
2018 Q2	$1K	Buy	21 +1	+5%	+$58	﹤0.01%	1558
2018 Q1	$1K	Hold	20	–	–	﹤0.01%	1569
2017 Q4	$1K	Hold	20	–	–	﹤0.01%	1543
2017 Q3	$1K	Hold	20	–	–	﹤0.01%	1503
2017 Q2	$1K	Hold	20	–	–	﹤0.01%	1423
2017 Q1	$1K	Buy	+20	New	+$1.08K	﹤0.01%	1314

Other funds holding PPH

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

WWM

Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Benjamin F. Edwards & Company's PPH Position: Q2 2019 in Review

Benjamin F. Edwards & Company sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2019, closing a stake of 21 shares — an estimated $1K sold.

Benjamin F. Edwards & Company first reported a position in PPH in Q1 2017 and held it in 9 quarters. The position peaked at $1K in Q1 2019. 41 funds tracked by Wall St. Rank hold PPH as of Q2 2019.

Benjamin F. Edwards & Company reported no remaining VanEck Pharmaceutical ETF position as of Q2 2019 after selling out during the quarter.
Benjamin F. Edwards & Company sold 21 VanEck Pharmaceutical ETF shares in Q2 2019, an estimated $1K.
Benjamin F. Edwards & Company first reported a position in VanEck Pharmaceutical ETF in Q1 2017 and held it in 9 quarters.
Benjamin F. Edwards & Company's VanEck Pharmaceutical ETF position peaked at $1K in Q1 2019.
41 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2019.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2019, filed 8 Aug 2019.